LANSING, Mich. – IONETIX, a leader in advanced radiopharmaceutical technologies, is investing $25.75 million to expand its Delta Township facility. The project will add a second cyclotron, and an advanced isotope processing laboratory. The expansion is expected to create 53 high-tech jobs and further accelerate innovation in life sciences and nuclear medicine manufacturing.
“IONETIX’s expansion is creating high-skill, high-value jobs and elevating the Lansing Region within the global medical technology landscape,” said Bob Trezise, president and CEO of the Lansing Economic Area Partnership (LEAP). “LEAP is proud to support this project and the ecosystem of innovative MedTech companies making our region a destination for biomedical research and economic opportunity.”
IONETIX marked the milestone with a community event at its Delta Township facility, bringing together company leaders, regional partners, and officials from across the state. Speakers included representatives from IONETIX, LEAP, the Michigan Economic Development Corporation (MEDC), and Delta Township.
Founded in 2009 from technology developed at the MIT Plasma Science and Fusion Center, IONETIX has pioneered the world’s first commercial compact superconducting cyclotron, the ION-12SC, which is used to produce N-13 ammonia, one of the most accurate positron emission tomography (PET) imaging agents for detecting coronary artery disease (CAD). The company has also expanded its focus to targeted alpha therapy (TAT), an emerging cancer treatment utilizing high-energy alpha particles to target cancer cells while preserving healthy tissue.
“Delta Township and the Lansing region offer the ideal environment for IONETIX’s continued growth. The area’s highly skilled workforce, robust infrastructure, and strong spirit of public-private collaboration make it the perfect location for our expansion,” said Kevin J. Cameron, Chief Executive Officer of IONETIX. “We are honored to invest in this community and proud that it is in the forefront of creating diagnostic and therapeutic innovations.”
This expansion aligns with IONETIX’s broader strategy to grow its radiopharmaceutical manufacturing network, advance commercialization of new therapies, and reinforce Michigan’s leadership in life sciences and medical technology innovation.
The State of Michigan, through the Michigan Business Development Program, awarded IONETIX $750,000 in incentives to support this expansion, ensuring a strong pipeline of skilled talent and continued innovation in the region.
We are thrilled with the company’s commitment to Michigan and the Lansing community by investing over $25 million to accelerate the efforts to one day cure cancer,” said Matt McCauley, Senior Vice President for Regional Development at the MEDC. “Team Michigan welcomes IONETIX Corporation’s expansion, furthering Michigan’s leadership in the life sciences and medical technology industries. We applaud the company’s vision to Make it in Michigan.
The IONETIX expansion reinforces Michigan’s strength in radiopharmaceutical innovation, building on Michigan State University’s no. 2 national ranking in nuclear physics and robust network of MedTech and life sciences companies across the region.
“Delta Township is proud to support IONETIX’s continued growth and the incredible impact this expansion will have on our local economy,” said Fonda Brewer, Delta Township Supervisor. “This investment not only brings dozens of high-tech, high-paying jobs to our community, but also solidifies Delta Township as a destination for cutting-edge MedTech innovation. We look forward to supporting IONETIX and the broader growth of Michigan’s life sciences sector.”
The addition of IONETIX to Michigan’s Health Core—a regional coalition of life sciences, healthcare, and technology leaders based in the Lansing Region—reaffirms the state’s position as a national leader in medical technology innovation.
About IONETIX
Utilizing its proprietary cyclotron technology platform, IONETIX has developed innovative solutions that enable access to scarce radioisotopes used for both diagnostic and therapeutic radiopharmaceuticals. IONETIX offers both high-purity Actinium-225 (Ac-225) and Astatine-211 (At-211) for use in targeted alpha therapies. IONETIX also provides N-13, F-18 and Ga-68 for diagnostic imaging. Its distribution supply chain includes contract drug manufacturing and “white glove” distribution logistics, allowing global access to these imaging agents and targeted radiotherapies. Contact us for more information.
